Welcome to the ECRAID-Prime study page

ECRAID-Prime is pioneering Europe's first adaptive platform trial aimed at evaluating new treatments for COVID-19 and COVID-like illnesses within community and primary care settings. This double-blind, randomised, comparative study focuses on the effects of Investigational Medicinal Products (IMPs) in non-hospitalised patients.

The EU-funded trial launched in October 2024, with Nitric Oxide Nasal Spray (NONS) and Saline nasal spray as the first investigational drugs being tested. 

“COVID-19 and COVID-like illness continue to have a profound impact on public health particularly within primary care and community settings, where the burden is the greatest. It is in these settings that early treatment options can deliver the most significant benefits. Our trial is focussed on finding effective treatments and making them available to those who need them most.” – Chris Butler, Principal Investigator

Nitric Oxide & Saline Nasal Sprays

This study aims to assess the efficacy of Nitric Oxide Nasal Spray (NONS) compared with intranasal saline, and intranasal saline compared with usual care in patients with COVID-19 and COVID-like illness to improve patient outcomes. 

Read more.

Covid and nose spray